Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study
Identifieur interne : 002107 ( Main/Corpus ); précédent : 002106; suivant : 002108Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study
Auteurs : Helge Hellriegel ; Jan Raethjen ; G. Deuschl ; Jens VolkmannSource :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
Abstract
Background:: In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. Methods:: Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36. Results:: We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: P = .079; SF‐36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate. Conclusions:: Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23881
Links to Exploration step
ISTEX:7D8F27B5732B3628C308C61E644D79ABC4F58DDFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title><author><name sortKey="Hellriegel, Helge" sort="Hellriegel, Helge" uniqKey="Hellriegel H" first="Helge" last="Hellriegel">Helge Hellriegel</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raethjen, Jan" sort="Raethjen, Jan" uniqKey="Raethjen J" first="Jan" last="Raethjen">Jan Raethjen</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, G" sort="Deuschl, G" uniqKey="Deuschl G" first="G." last="Deuschl">G. Deuschl</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Volkmann, Jens" sort="Volkmann, Jens" uniqKey="Volkmann J" first="Jens" last="Volkmann">Jens Volkmann</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7D8F27B5732B3628C308C61E644D79ABC4F58DDF</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23881</idno><idno type="url">https://api.istex.fr/document/7D8F27B5732B3628C308C61E644D79ABC4F58DDF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002107</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title><author><name sortKey="Hellriegel, Helge" sort="Hellriegel, Helge" uniqKey="Hellriegel H" first="Helge" last="Hellriegel">Helge Hellriegel</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raethjen, Jan" sort="Raethjen, Jan" uniqKey="Raethjen J" first="Jan" last="Raethjen">Jan Raethjen</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, G" sort="Deuschl, G" uniqKey="Deuschl G" first="G." last="Deuschl">G. Deuschl</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Volkmann, Jens" sort="Volkmann, Jens" uniqKey="Volkmann J" first="Jens" last="Volkmann">Jens Volkmann</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2431">2431</biblScope><biblScope unit="page" to="2434">2434</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7D8F27B5732B3628C308C61E644D79ABC4F58DDF</idno><idno type="DOI">10.1002/mds.23881</idno><idno type="ArticleID">MDS23881</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>clinical neurology</term><term>clinical trials</term><term>levetiracetam</term><term>orthostatic tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:: In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. Methods:: Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36. Results:: We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: P = .079; SF‐36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate. Conclusions:: Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Helge Hellriegel MD</name><affiliations><json:string>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</json:string></affiliations></json:item><json:item><name>Jan Raethjen MD, PhD</name><affiliations><json:string>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</json:string></affiliations></json:item><json:item><name>G. Deuschl MD, PhD</name><affiliations><json:string>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</json:string></affiliations></json:item><json:item><name>Jens Volkmann MD, PhD</name><affiliations><json:string>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>clinical neurology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trials</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>orthostatic tremor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levetiracetam</value></json:item></subject><articleId><json:string>MDS23881</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background:: In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. Methods:: Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36. Results:: We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: P = .079; SF‐36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate. Conclusions:: Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.932</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1048</abstractCharCount><pdfWordCount>14214</pdfWordCount><pdfCharCount>97058</pdfCharCount><pdfPageCount>23</pdfPageCount><abstractWordCount>161</abstractWordCount></qualityIndicators><title>Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>2434</last><first>2431</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23881</json:string></doi><id>7D8F27B5732B3628C308C61E644D79ABC4F58DDF</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/7D8F27B5732B3628C308C61E644D79ABC4F58DDF/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/7D8F27B5732B3628C308C61E644D79ABC4F58DDF/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7D8F27B5732B3628C308C61E644D79ABC4F58DDF/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This study was sponsored by UCB Pharma GmbH.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title><author><persName><forename type="first">Helge</forename><surname>Hellriegel</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation></author><author><persName><forename type="first">Jan</forename><surname>Raethjen</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University Hospital Schleswig‐ Holstein, Campus Kiel, Haus 41, Arnold‐Heller‐Str. 3, 24105 Kiel, Germany</p></note><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation></author><author><persName><forename type="first">G.</forename><surname>Deuschl</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation></author><author><persName><forename type="first">Jens</forename><surname>Volkmann</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2431">2431</biblScope><biblScope unit="page" to="2434">2434</biblScope></imprint></monogr><idno type="istex">7D8F27B5732B3628C308C61E644D79ABC4F58DDF</idno><idno type="DOI">10.1002/mds.23881</idno><idno type="ArticleID">MDS23881</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:: In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. Methods:: Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36. Results:: We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: P = .079; SF‐36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate. Conclusions:: Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>clinical neurology</term></item><item><term>clinical trials</term></item><item><term>orthostatic tremor</term></item><item><term>levetiracetam</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02-07">Received</change><change when="2011-06-15">Registration</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/7D8F27B5732B3628C308C61E644D79ABC4F58DDF/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v26.13</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2011-11">November 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="220" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23881</doi><idGroup><id type="unit" value="MDS23881"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-07"></event><event type="manuscriptRevised" date="2011-06-10"></event><event type="manuscriptAccepted" date="2011-06-15"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-09-23"></event><event type="publishedOnlineFinalForm" date="2011-11-22"></event><event type="firstOnline" date="2011-09-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2431</numbering><numbering type="pageLast">2434</numbering></numberingGroup><correspondenceTo>Department of Neurology, University Hospital Schleswig‐ Holstein, Campus Kiel, Haus 41, Arnold‐Heller‐Str. 3, 24105 Kiel, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23881.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="3049"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study<link href="#fn1"></link><link href="#fn2"></link><link href="#fn3"></link></title><title type="short" xml:lang="en">Levetiracetam in Orthostatic Tremor</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Helge</givenNames><familyName>Hellriegel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jan</givenNames><familyName>Raethjen</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="j.raethjen@neurologie.uni-kiel.de">j.raethjen@neurologie.uni‐kiel.de</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>G.</givenNames><familyName>Deuschl</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jens</givenNames><familyName>Volkmann</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">clinical neurology</keyword><keyword xml:id="kwd2">clinical trials</keyword><keyword xml:id="kwd3">orthostatic tremor</keyword><keyword xml:id="kwd4">levetiracetam</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>We found no significant effect of dosage or treatment on stance duration (<i>P</i> = .175), total track length (<i>P</i> = .690), total power (<i>P</i> = .280), or visual analog scale (<i>P</i> =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: <i>P</i> = .079; SF‐36, Mental Component Summary: <i>P</i> = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Funding agencies</b>: This study was sponsored by UCB Pharma GmbH.</p></note><note xml:id="fn2"><p><b>Relevant conflicts of interest/financial disclosures</b>: Nothing to report.</p></note><note xml:id="fn3"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levetiracetam in Orthostatic Tremor</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study</title></titleInfo><name type="personal"><namePart type="given">Helge</namePart><namePart type="family">Hellriegel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jan</namePart><namePart type="family">Raethjen</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation><description>Correspondence: Department of Neurology, University Hospital Schleswig‐ Holstein, Campus Kiel, Haus 41, Arnold‐Heller‐Str. 3, 24105 Kiel, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Deuschl</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jens</namePart><namePart type="family">Volkmann</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Christian‐Albrechts‐University, Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCaptured encoding="w3cdtf">2011-02-07</dateCaptured><dateValid encoding="w3cdtf">2011-06-15</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">17</extent><extent unit="words">3049</extent></physicalDescription><abstract lang="en">Background:: In a double‐blind crossover study we evaluated the antitremor effect of a 4‐week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor. Methods:: Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF‐36. Results:: We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF‐36 differentially changed by levetiracetam or placebo (SF‐36, Physical Component Summary: P = .079; SF‐36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate. Conclusions:: Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This study was sponsored by UCB Pharma GmbH.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>clinical neurology</topic><topic>clinical trials</topic><topic>orthostatic tremor</topic><topic>levetiracetam</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2431</start><end>2434</end><total>4</total></extent></part></relatedItem><identifier type="istex">7D8F27B5732B3628C308C61E644D79ABC4F58DDF</identifier><identifier type="DOI">10.1002/mds.23881</identifier><identifier type="ArticleID">MDS23881</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002107 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002107 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:7D8F27B5732B3628C308C61E644D79ABC4F58DDF
|texte= Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study
}}
| This area was generated with Dilib version V0.6.23. |  |